AbbVie Rx hit: $150M

AbbVie was ordered to pay $150 million to an Oregon man who accused the drugmaker of hiding the heart-attack risks of its AndroGel testosterone booster, a stinging loss in its first case to be weighed by jurors over what was once one of its top-selling products.